Vaxart (NASDAQ:VXRT) is up 15% premarket on robust volume in reaction to its announcement of
positive preclinical data on its oral COVID-19 vaccine candidates,
several of which generated immune responses in all tested animals after a
single dose.
CSO Sean Tucker, Ph.D., says, “These preclinical
results confirm that all constructs are immunogenic as measured by IgG
antibodies in serum and we observed a robust boosting effect after the
second dose. This latest data set will help to select the lead candidate
for manufacturing and we remain on track to start a first phase 1 study
in the second half of this year.”
Orally administered vaccines, while preferable to
the injected variety assuming comparable immunogenicity, have always
been more challenging to develop due to the harsh conditions in the
human digestive tract.
https://seekingalpha.com/news/3566947-vaxart-up-15-premarket-on-encouraging-data-on-oral-covidminus-19-vaccine-candidates
No comments:
Post a Comment
Note: Only a member of this blog may post a comment.